141 related articles for article (PubMed ID: 9527404)
1. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.
Hou FF; Boyce J; Chertow GM; Kay J; Owen WF
J Am Soc Nephrol; 1998 Feb; 9(2):277-83. PubMed ID: 9527404
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of amyloid beta2-microglobulin and modification with advanced glycation end products.
Mironova R; Niwa T
J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(1):109-15. PubMed ID: 11482729
[TBL] [Abstract][Full Text] [Related]
3. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
[TBL] [Abstract][Full Text] [Related]
4. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G
J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976
[TBL] [Abstract][Full Text] [Related]
5. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.
Degenhardt TP; Fu MX; Voss E; Reiff K; Neidlein R; Strein K; Thorpe SR; Baynes JW; Reiter R
Diabetes Res Clin Pract; 1999 Feb; 43(2):81-9. PubMed ID: 10221660
[TBL] [Abstract][Full Text] [Related]
6. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis.
Niwa T; Sato M; Katsuzaki T; Tomoo T; Miyazaki T; Tatemichi N; Takei Y; Kondo T
Kidney Int; 1996 Oct; 50(4):1303-9. PubMed ID: 8887292
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.
Matsuo K; Ikizler TA; Hoover RL; Nakamoto M; Yasunaga C; Pupim LB; Hakim RM
Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
9. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.
Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877
[TBL] [Abstract][Full Text] [Related]
10. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
[TBL] [Abstract][Full Text] [Related]
11. The effect of an insulin releasing agent, BTS 67582, on advanced glycation end product formation in vitro.
Simpson AE; Jones RB
Life Sci; 1999; 64(16):1427-34. PubMed ID: 10321722
[TBL] [Abstract][Full Text] [Related]
12. Modification of beta 2-microglobulin with D-glucose or 3-deoxyglucosone inhibits A beta 2M amyloid fibril extension in vitro.
Hashimoto N; Naiki H; Gejyo F
Amyloid; 1999 Dec; 6(4):256-64. PubMed ID: 10611946
[TBL] [Abstract][Full Text] [Related]
13. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications.
Yu PH; Zuo DM
Diabetologia; 1997 Nov; 40(11):1243-50. PubMed ID: 9389414
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal.
Taguchi T; Sugiura M; Hamada Y; Miwa I
Eur J Pharmacol; 1999 Aug; 378(3):283-9. PubMed ID: 10493104
[TBL] [Abstract][Full Text] [Related]
15. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats.
Kochakian M; Manjula BN; Egan JJ
Diabetes; 1996 Dec; 45(12):1694-700. PubMed ID: 8922353
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques.
Imanaga Y; Sakata N; Takebayashi S; Matsunaga A; Sasaki J; Arakawa K; Nagai R; Horiuchi S; Itabe H; Takano T
Atherosclerosis; 2000 Jun; 150(2):343-55. PubMed ID: 10856526
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.
Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K
J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine.
Edelstein D; Brownlee M
Diabetes; 1992 Jan; 41(1):26-9. PubMed ID: 1727735
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in Streptozotocin-treated diabetic rats.
Yamabe N; Kang KS; Goto E; Tanaka T; Yokozawa T
Biol Pharm Bull; 2007 Mar; 30(3):520-6. PubMed ID: 17329849
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products induce crosslinking of collagen in vitro.
Sajithlal GB; Chithra P; Chandrakasan G
Biochim Biophys Acta; 1998 Sep; 1407(3):215-24. PubMed ID: 9748585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
